Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 8/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | NMT2 | O60551 | 3/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486507 | 0.92 | TLR7 (0.47) | NMT1TLR7NMT2ACSS2HRH3 | |
| SCHEMBL1486585 | 0.90 | NMT1 (0.42) | NMT1NMT2HRH3IP6K1 | |
| SCHEMBL1486756 | 0.88 | NMT1 (0.44) | NMT1NMT2ACSS2IP6K1 | |
| SCHEMBL4541234 | 0.86 | MAPT (0.44) | NMT1NMT2ACSS2IP6K1 | |
| SCHEMBL1486719 | 0.85 | TLR8 (0.44) | NMT1TLR7NMT2ACSS2IP6K1 | |
| SCHEMBL1486619 | 0.85 | TLR8 (0.52) | NMT1TLR7NMT2ACSS2IP6K1 | |
| SCHEMBL1486567 | 0.85 | TLR7 (0.62) | TLR7 | |
| SCHEMBL6722232 | 0.83 | TLR7 (0.50) | TLR7 | |
| SCHEMBL1486497 | 0.83 | HRH3 (0.42) | NMT1TLR7NMT2ACSS2HRH3 | |
| SCHEMBL1486524 | 0.83 | TLR7 (0.40) | NMT1TLR7NMT2ACSS2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-7897597-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1658076-A4 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-15 | — | — | US | disclosed |
| EP-1658076-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005020999-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | IL2, IFNG, IRF3 | NMT1 3893/4885TLR7 45/4885NMT2 3463/4885 |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | NMT1 3677/4885TLR7 42/4885NMT2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.